DFB Soria

DFB Soria LLC, an affiliate of NanOlogy, is owned and operated by DFB Pharmaceuticals. Soria has entered into a global exclusive license agreement with CritiTech to use its submicron particle production technology in certain fields outside oncology, including dermatology. The submicron paclitaxel particles contained in Soria’s products are manufactured using proprietary production technology that reduces the size of raw paclitaxel API crystals to 400 times smaller, forming stable, uncoated, pure drug particles with an exponentially increased surface area and unique geometry.